| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
MQAE (N-[ethoxycarbonylmethyl]-6-methoxy-quinolinium bromide) is an analog of 6-methoxyquinolinium. It is a novel fluorescent indicator/dye for detection of intracellular Cl-. MQAE detects the ion when quenched via collision with chloride. It is more frequently used for chloride measurement as it is more sensitive and selective than 36Cl and microelectrode-based methods. MQAE is a useful fluorescence dye for noninvasive measurements of the intracellular Cl-.
| ln Vitro |
Preparation of MQAE Working Solution Using Method 1 Dilute the stock solution in Krebs-hepes buffer (20 mM HEPES, 128 mM NaCl, 2.5 mM KCl, 2.7 mM CaCl2, 1 mM MgCl2, 16 mM glucose, pH 7.4) to obtain 5- 10 mM MQAE working solution. Note: Please prepare the MQAE working fluid for immediate use by adjusting its concentration to the current circumstances. 2 Cell staining 2.1 Use Krebs-HEPES buffer to wash cells 3 times, 2 minutes each time. 2.2 Add 1 milliliter of the MQAE working solution, then let it sit at room temperature for 30 to 60 minutes. 2.3 After adding PBS, wash the cells twice for five minutes each. 2.4 Use a flow cytometer or fluorescence microscope to make observations. 3 Storage conditions -20°C, protected from light for one year 4 Notes 4.1 It is recommended to use MQAE for staining. 8–10×106/mL is the suggested cell density. 4.2 Please modify the incubation period and concentration of the MQAE working solution based on the actual circumstances. 4.3 This product should only be used by experts conducting scientific research; it should not be incorporated into food or medication, nor used for clinical diagnosis or treatment. 4.4 Please wear disposable gloves and a lab coat for your health and safety.
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
[1]. Kovalchuk Y, et al. Two-photon chloride imaging using MQAE in vitro and in vivo. Cold Spring Harb Protoc. 2012 Jul 1;2012(7):778-85.
[2]. Andersson C, et al. Determination of chloride efflux by X-ray microanalysis versus MQAE-fluorescence. Microsc Res Tech. 2 [3]. Koncz C, et al. Use of MQAE for measurement of intracellular [Cl-] in cultured aortic smooth muscle cells. Am J Physiol. 1994 Dec;267(6 Pt 2):H2114-23. |
| Molecular Formula |
C14H16BRNO3
|
|
|---|---|---|
| Molecular Weight |
326.19
|
|
| CAS # |
162558-52-3
|
|
| Related CAS # |
|
|
| SMILES |
COC1=CC2=CC=C[N+](CC(OCC)=O)=C2C=C1.[Br-]
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0657 mL | 15.3285 mL | 30.6570 mL | |
| 5 mM | 0.6131 mL | 3.0657 mL | 6.1314 mL | |
| 10 mM | 0.3066 mL | 1.5328 mL | 3.0657 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02254551 | Terminated Has Results | Drug: LDE225 Drug: Bortezomib |
Multiple Myeloma | SCRI Development Innovations, LLC | January 2015 | Phase 2 |
| NCT04066504 | Active, not recruiting | Drug: sonidegib | Basal Cell Carcinoma | Sun Pharmaceutical Industries Limited | March 11, 2019 | |
| NCT02086513 | Terminated | Drug: LDE225 | Graft Versus Host Disease | Massachusetts General Hospital | April 2014 | Phase 1 |
| NCT04007744 | Recruiting | Biological: Pembrolizumab Drug: Sonidegib |
Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage III Gastric Cancer AJCC v8 |
Mayo Clinic | February 13, 2020 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA